Current Stage

Transcription

Current Stage

Alcon innovation –
Accelerating Growth
Kevin Buehler
Alcon Division Head
Investor Day
London, 22 November 2013
Disclaimer
This presentation contains forward-looking statements that can be identified by terminology such as such as “potential,” “expected,” “will,” “planned,”
or similar expressions, or by express or implied discussions regarding potential new products, potential new indications for existing products, or
regarding potential future revenues from any such products; the potential completion of the divestiture of the Novartis blood transfusion diagnostics
unit; potential shareholder returns or credit ratings, the potential outcome of the share buyback being initiated; or regarding potential future sales or
earnings of the Novartis Group or any of its divisions; or by discussions of strategy, plans, expectations or intentions. You should not place undue
reliance on these statements. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and
unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or
achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or
that any new indications will be approved for any existing products in any market, or that any approvals which are obtained will be obtained at any
particular time, or that any such products will achieve any particular revenue levels. Nor can there be any guarantee that the proposed divestiture of
the blood transfusion diagnostics unit will be completed in the expected form or within the expected time frame or at all. Nor can there be any
guarantee that Novartis will be able to realize any of the potential strategic benefits, synergies or opportunities as a result of the divestiture. Neither
can there be any guarantee that shareholders will achieve any particular level of shareholder returns or regarding the potential outcome of the share
buyback being initiated. Nor can there be any guarantee that the Group, or any of its divisions, will achieve any particular financial results or any
particular credit rating. In particular, management's expectations could be affected by, among other things, unexpected regulatory actions or delays or
government regulation generally, including an unexpected failure to obtain necessary government approvals for the transaction, or unexpected delays
in obtaining such approvals; the potential that the potential strategic benefits, synergies or opportunities expected from the transaction may not be
realized or may take longer to realize than expected; the inherent uncertainties involved in predicting shareholder returns or credit ratings; unexpected
clinical trial results, including additional analyses of existing clinical data or unexpected new clinical data; the Group's ability to obtain or maintain
patent or other proprietary intellectual property protection, including the ultimate extent of the impact on the Group of the loss of patent protection and
exclusivity on key products which commenced last year and will continue this year; unexpected product manufacturing and quality issues, including
the resolution of the Warning Letter issued to us with respect to three Sandoz manufacturing facilities, and the completion of efforts to restart
production of certain products formerly produced at the Consumer Health manufacturing facility at Lincoln, Nebraska, and the restructuring efforts at
that site; government, industry, and general public pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among
others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, shareholder litigation,
government investigations and intellectual property disputes; competition in general; uncertainties regarding the effects of the ongoing global financial
and economic crisis, including the financial troubles in certain Eurozone countries; uncertainties regarding future global exchange rates; uncertainties
regarding future demand for our products; uncertainties involved in the development of new healthcare products; the impact that the foregoing factors
could have on the values attributed to the Group's assets and liabilities as recorded in the Group's consolidated balance sheet; and other risks and
factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as
anticipated, believed, estimated or expected. Novartis is providing the information in this presentation as of this date and does not undertake any
obligation to update any forward-looking statements as a result of new information, future events or otherwise.
| Investor Day | 22 November 2013 |
Agenda
Perspectives post-merger
Surgical: transformational innovation for patients and clinicians
Ophthalmic Pharmaceuticals: near and long-term drivers
Vision Care: now a critical mass competitor
Looking ahead and Conclusions
59
Substantial innovation since merger
Timing of Value Driver
Franchise
Near-Term
 Glaucoma combinations
Ophthalmic
Pharmaceuticals
offsetting generic pressures
 Enter retina space: Jetrea®
Longer-Term (>3 years)
 NIBR integration with
program acceleration
 Novel NMEs: ESBA 1008
and complement inhibitors
 Launch of Centurion® phacoemulsification system
Surgical
 Launch of Cataract Refractive
 Increasing AT-IOL penetration
 Emerging Markets conversion
to Phaco
Suite™
 Successful integration of lens
 Broaden portfolio to fill gaps
care and contact lens portfolio
Vision Care
 New product launches in key
segments
 Cost synergies of USD 370 m
 Integration into Novartis and
business realignment
60
Completion
Underway
Eyecare remains attractive with projected growth in
mid-single digits
Projected industry sales
USD bn
Drivers
49
+4%
11
Vision Care
13
Surgical
37
9
+7%
9
+5%
25
19
2013
+5%
 Shift towards disposable contact lenses
 Shift towards SiHy material
 Emerging market penetration
 Cataract procedure growth
 Adoption and penetration of AT-IOLs
 New equipment platforms
Ophthalmic
 Continued expansion of Retina therapies
Pharmaceuticals
 Growth in glaucoma combinations offset by LOEs
 Unit volume driven by aging demographics
2018
Source
(1) Contact Lens and Lens Care estimates Contact Lens Institute/Euromcontact Factory Sales Sharing Program/GfK/Internal Estimates; Market definition limited
to Soft lens, and disinfectant solutions
(2) Pharmaceuticals estimates according to IMS MIDAS, 2012
(3) Surgical estimates according to 2013 Market Scope, LLC Forecasts
(4) Retina Rx from Evaluate Pharma estimations, 2013
(5) Vitamins estimates based on Nielsen, Japan Euromonitor, and IMS GlobalTrak.
61
Agenda
62
Ophthalmic surgical: attractive space multiple facets
driving growth
Industry Growth Drivers
Projected 2013 surgical
industry sales in USD bn
Cataract
Projected
Alcon
CAGR
Position
13-18
7.2
7%
 Rising global cataract procedures
 Increasing AT-IOL penetration
 Increasing adoption of phacoemulsification
#1
Alcon Growth Drivers
Vitreoretinal
Refractive
1.0
0.5
Total
5%
#1
4%
#2
7%
 Launch of Centurion® Vision System for
phacoemulsification
 Launch of Cataract Refractive Suite™
 Focus on Toric AT-IOLs
 Smaller incision, preloaded IOL launch
 Phacoemuslification development
Source: Surgical estimates according to 2013 Market Scope, LLC Forecasts, Internal estimates
63
Demographic trends plus innovation expected to
deliver surgical growth
Illustrative
Projected Alcon Surgical Growth
Cataract Refractive
Suite™ launch
IOL upgrades
Centurion®
Vision System
~ 5%
Procedure
Growth
64
Equipment
Share and Price
AT-IOL
Penetration
Continued innovation in surgical expected to further
patient and surgeon needs
Market expansion
Surgical
LenSx®
ReSTOR® 2.5D
Intrepid®
Femtosecond
cataract laser
Multi-focal
Intraocular Lens
Minimally Invasive
Intraocular Lens
Luxor® LX3
Verion™ Integration
Microscopes
LenSx and Centurion®
Centurion®
Phacoemulsification
EX500® / FS200®
Refractive surgery
lasers
Ophthalmic
Pharmaceuticals
Short Term (<3 years)
Simbrinza®
Glaucoma
Dailies Total1®
SiHy Lens
1sVMA=
symptomatic Vitreomacular Adhesion
= Geographic Atrophy
3AMD = Age-related Macular Degeneration
4DACP = Dailies Aqua Comfort Plus ®
5DT1 = Dailies Total 1®
6WG = Water Gradient
2GA
65
Accommodative
Next generation
Intraocular Lens
Vitreo-retinal system
Discussed
Today
ReSTOR® Toric
Intraocular Lens
LD Travoprost
Glaucoma
HD Olopatadine
Allergy
Jetrea®
sVMA1
Vision Care
Longer Term (>3 years)
ESBA 1008
Wet AMD3
PDE IV
Allergy
DACP4 Toric
HEMA lens
AirOptix® Color
SiHy Lens
DACP4 Multifocal
HEMA lens
Replenish® w/
ESBA1008
Wet AMD3
Complement
Inhibitor
GA2
DT15 Multifocal
SiHy Lens
DT15 Toric
SiHy Lens
DT15 Colors
SiHy Lens
Weekly WG6
SiHy Lens
Centurion® is expected to allow Alcon to expand its
leading position in phaco equipment
Key Differentiators
Key Differentiators
 “Active Fluidics” – Improvement in
Intraocular Pressure (IOP) stability
 Intuitive Touch Screen Graphic User
Interface
 VERION™ Link
Current Stage Current Stage
 CE mark and FDA approval in late 2012
 Commercial launch Q4 2013
66
Alcon offers a range of base and advanced technology
IOLs
Base
IOL Comparison
Advanced technology
Product
Description
Value
67
base
monofocal
USD
Base Value
smaller
incision
Base
Value+
addresses
astigmatism
3x
Base Value
addresses
presbyopia
5x
Base Value
addresses
astigmatism and
presbyopia
7x
Base Value
Intrepid® IOL platform offers the ability to provide
smaller incision size
Key Differentiators
Key Differentiators
 Real sub 2mm procedure
 Maintains wound integrity
• Less damage to corneal endothelium
• Less surgically induced astigmatism
 Preloaded to reduce handling
 Compatible with AUTOSERT™ IOL Injector
Centurion® and INFINITI® Systems
 Targeted launch expected in H1 2014
68
Innovation in Multi-Focal IOLs
ReSTOR® Toric
ReSTOR® 2.5D
Key Differentiators
Key Differentiators
 Corrects astigmatism and
 Shift light energy to the distance
presbyopia
 Provides broadest range (nearintermediate-distance) of vision
 High level of spectacle
independence
 Improves quality of both
distance and intermediate vision
 Potentially reduces halo and
glare
Current Stage
Current Stage
 US and Japan launch expected
 Launched in EU in Q3 2012
 Clinical trials ongoing to support
in
2nd
half of 2014
 Commercially available in all
other markets
69
image
US filing
An unmet need exists to help provide better refractive
outcomes for cataract patients...
In the Clinic
 Preoperative
measurement
 Surgical planning and
IOL selection
~40% of cataract patients
have >1D of astigmatism1
1
W Hill Keratometry database
70
During Surgery
 Marking for lens
alignment
 Precise placement
Aiding in these steps can drive better
patient outcomes
... which can be improved through an integrated
approach to surgical planning
Elements of the Cataract Refractive Suite™
Pre-operative imaging and
planning
Femtosecond laser for
incisions and to soften lens
LenSx® disposables
71
AT-IOLs
Superior intra-operative
visualization
New phacoemulsification
platform enhancing control
Procedure Items
The launch of the Cataract Refractive Suite™ could
shift the paradigm in cataract surgery
Video on Verion™ Image Guided System is shown at the event
72
Plans to increase the Toric AT-IOL penetration
Penetration of clinically eligible > 1D
astigmatism procedures
Plan to Improve Toric Penetration
50%
 Maximize patient access by market
 Build clinical confidence via
40%
technology (e.g. VERION™,
ReSTOR® Toric, ReSTOR® 2.5D
Toric)
30%
 Patient engagement
20%
10%
Australia US
Japan France Brazil Germany Italy
Sources:
(1) 2013 Global IOL Report (Market Scope)
(2) W Hill Keratometry database
(3) AcrySof IQ ReSTOR Multifocal IOL DFU Warnings/Precautions. Schmier et al. Evaluation of Medicare Costs of Endophthalmitis among Patients after
Cataract Surgery. Ophthalmology 2007
73
Patient engagement could make a step change in
treatment
FreedomFromCataracts.com
EyeFile Registration
Site registration including
personalization and
opportunities to opt-in for
additional information
74
Surgeon Locator
Patient Information Kit
Local search for surgeons that
perform AT-IOL procedures and
use femtosecond lasers
Information related to disease
awareness, treatment options,
and physician discussion guide
Phaco Development in Emerging Markets
Px
1.3M
Penetration* % Phaco
0.8%
Goals
Status in 2013
 Increase penetration – by
building surgical capacity
 Program trained
surgeons performed
111k procedures
70%
 Standardized phaco
development program
China
6.3M
6.8%
24%
 Increase usage of phaco emulsification
 Partnerships with private and
government teaching centers
India
455k
0.2%
89%**
 Increased penetration by
building surgical capacity and
patient access to capable
Phaco surgeons
3.5M
6.0%
99%
 Standard of care for cataract
procedures
Russia
US
* Procedure penetration in >60 year olds as estimated by UN Population Division
Source: Market Scope 2013 ; **internal estimate
75
 Program trained
surgeons performed
76k procedures
 4 Pilots focused on
high potential
underserved regions
Surgical Summary
Surgical expected to grow faster than the industry driven by
 Expected tailwinds from cataract procedure growth from
demographics and emerging markets
 Focus on patient outcomes
 Expected increase in toric AT-IOL penetration
76
Agenda
77
Ophthalmic pharmaceuticals: attractive opportunities
expected to offset generic pressures
Projected
CAGR Alcon
Projected 2013 pharmaceutical
13-18 Position
Glaucoma
Infection
Inflammation
Dry Eye
Allergy
Otic
5.2
0%
#1
 New Retinal approvals and unmet clinical
need
 Limited Glaucoma NME innovation and
generic pressure
 Aging demographics drive unit volume
 Emerging market adoption of Rx technology
2.7
2.2
Total
#1
3%
#2
5%
2.1
Retina
3%
#1
 Jetrea® – new standard of treatment for
VMT
 Combination Glaucoma growth – OUS and
Simbrinza® opportunity
6.4
11%
5%
#1*
 Growth potential for palliative dry eye
treatment – Systane®
 Pipeline opportunities in anti-VEGF and
Complement Factor – POC stage
* Including Lucentis®
Source: Pharmaceuticals estimates according to IMS MIDAS, 2012; Retina Rx from Evaluate Pharma estimations, 2013
78
Combination glaucoma is expected to be a growth
driver for Alcon
Projected contribution to global glaucoma sales
(Illustrative)
 DuoTrav® and Azarga® combinations
continuing to drive growth ex-US
100%
 2013 Japan Azorga® approval
Monotherapies
(Travatan®, Azopt®)
 Simbrinza®:
• First beta-blocker free combination
in US
• Treatment option for systemic risk
patients
• US approval May 2013
• EU launch expected 2014
Combinations
(Duotrav®, Azarga®,
Simbrinza®)
2013
79
2018
 Assessing surgical intervention
technologies
Simbrinza® Creates New Treatment Possibilities
 Simbrinza®: beta-blocker-free/ timolol-free fixed
dose combination
 Provides additional treatment possibilities for
patients that cannot tolerate beta blockers
1
Market
US
EU
Regulatory
FDA approval
April 2013
EU submission
June 2013
Dosage
TID1
BID2
IOP lowering
(%, mmHg)
23-35%
6-9 mmHg
25-37%
7-10 mmHg
TID – Three times daily
2
BID – Twice daily
Source: G. Katz, JAMA Ophthalmol, April11, 2013, “Three month randomized trial of Fixed Combination Brinzolamide, 1%, and Brimonidine, 0.2%
80
Systane® franchise expected to continue to drive
growth
Alcon Dry Eye Sales
In USD m
Market Growth Drivers
 Aging population and increasing
600
disease awareness
+9%
 Under-penetration as currently 1 in 10
seek treatment
400
200
 Portfolio: Expand Systane® portfolio
across lubricating agents and
preservative options
0
2010
2011
2012
Exceeds estimated
industry growth of 4%
81
 Professional Demand: Increase trial
via professional recommendation
 OTC: Increase retail and consumer
awareness
Jetrea® will offer eligible patients an option
beyond watchful waiting and surgery
Diagnosis
Indication
Clinical Results
Jetrea® indicated for
treatment of VMT
including when
associated with
macular hole ≤400μm
26.4% resolution at 28
days across indicated
population
Visual acuity Loss
Vitreomacular traction
and macular hole
Source: Stalmans P et al. N Engl J Med 2012; 367: 606-15; Data on file
82
A multi-prong strategy is being executed to
develop the market for Jetrea®
Completion
Underway
Drive best in class launch
Creating the market for
new treatment approach
Registration with label
Demand creation to complete
retina community collaboration
with Novartis Ophthalmics
Market Access: Positive NICE
and IQWiG assessment
Real-world data generation:
Patient registry and Phase IV
Clinical data with efficacy
Estimated 250-300K patients in EU
IQWiQ - Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Healthcare)
Source: Novartis estimates
83
Ophthalmic Pharmaceuticals portfolio conversion
expected to drive growth, with LOE1 risk
Projected global sales potential
 Combination glaucoma growth and
Illustrative
share expansion (e.g. Duotrav®,
Azarga®, Simbrinza®)
 Jetrea®
• Acceleration with clinical experience
Strategic Brands &
Pipeline
and reimbursement
• Global launches
 Global expansion of the Systane® dry
eye franchise
 Potential upsides with ESBA 1008 and
complement inhibitors
 Retinal Pharmaceutical drug delivery -
LOE1 Brands
2013
2018
1
Loss of Exclusivity in Glaucoma and Allergy
Replenish is a trademark of Replenish, Inc
84
Replenish™
Pipeline with late term retinal opportunities
Market expansion
Surgical
LenSx®
ReSTOR® 2.5D
Intrepid®
Femtosecond
cataract laser
Multi-focal
Intraocular Lens
Minimally Invasive
Intraocular Lens
Luxor® LX3
Microscopes
Centurion®
Phacoemulsification
EX500® /FS200®
Refractive surgery
lasers
Ophthalmic
Pharmaceuticals
Simbrinza®
Glaucoma
Dailies Total1®
SiHy Lens
1sVMA=
= Geographic Atrophy
Replenish is a trademark of Replenish, Inc
2GA
85
Accommodative
Next generation
Intraocular Lens
Discussed
Today
ReSTOR® Toric
Intraocular Lens
LD Travoprost
Glaucoma
HD Olopatadine
Allergy
Jetrea®
sVMA1
Vision Care
ESBA 1008
Wet AMD3
PDE IV
Allergy
DACP4 Toric
HEMA lens
AirOptix® Color
SiHy Lens
DACP4 Multifocal
HEMA lens
Replenish® w/
ESBA1008
Wet AMD3
Complement
Inhibitor
GA2
DT15 Multifocal
SiHy Lens
DT15 Toric
SiHy Lens
DT15 Colors
SiHy Lens
Weekly WG6
SiHy Lens
ESBA 1008 has the potential to augment wet AMD
therapies
Key Differentiators
Key Differentiators
 Potentially longer duration of action versus
currently marketed anti-VEGFs
 Single chain antibody fragment (scFv)
smaller than a Mab or Fab
 Suitable for delivery via intravitreal treatment
or sustained drug delivery
 Phase II in Wet AMD
 Potential for three VEGF-dependent
indications (wet AMD1, DME2, RVO3)
®
1AMD
– Age related Macular Degeneration
– Diabetic macular edema
3RVO – Retinal vein occlusion
2DME
86
Replenish® drug delivery pump may provide an
alternative to intravitreal injection
Key Differentiators
 Fully programmable, refillable pump
 Versatile, can be used with multiple drugs
and formulations
 Rechargeable to support chronic use
 Applicable to back of the eye disorders
 Collaborating with leading technology firm
 First-in Human (FIH) study complete
 Next step: Replenish®/ESBA1008 Proof-ofConcept
Replenish® is a trademark of Replenish, Inc
87
Opportunity for Alcon to enter +USD 6 bn new category
Projected Global Sales for Wet
AMD, DME and RVO Therapies
In USD bn
 Continued growth projected, driven by
new indications
+10%
10.2
 Expanding clinical experience and
market access
RVO
DME
6.4
 Significant unmet need with need for
new NME treatments
wAMD
 Dose reduction and convenience
technologies are needed
2013
1
Evaluate Pharma
88
2018
LFG316 Complement Inhibitor for Geographic Atrophy
Key Differentiators
 Advanced form of dry AMD (~8 m patients
WW) characterized by the permanent blind
spots in a patient’s central vision1
 No therapy exists for treatment
 Potential to treat total population vs.
subpopulation with better response to
treatment
Current Stage
 Phase I ongoing, expected 2014 readout
1. Rudnicka, A. et al,"Age and Gender Variations in Age-related Macular Degeneration Prevalence in
Populations of European Ancestry: A Meta-analysis,"Ophthalmology, 2012; 119:571–580.
89
Ophthalmic Pharmaceuticals summary
Ophthalmic Pharmaceuticals will be driven by portfolio conversion
 Shift to combination glaucoma
 Continued growth of Systane® for dry-eye
 Progress in positioning Jetrea® as standard of care
 Innovation in retina treatments
90
Agenda
91
Alcon Vision Care unit fully aligned to capture growth
opportunities
 Shift to products with better outcomes
Projected 2013 Vision Care
Projected
CAGR Alcon
13-18 Position
(daily SiHy)
 Unmet need in comfort, vision, and
health
 Emerging growth markets in Asia
Soft Lenses
Lens Care
7.6
1.4
Total
4%
1%
4%
#2
#1
 Portfolio and Brand Development
• Re-launch and rebranding of Dailies
Aqua Comfort Plus®
• Launch of AirOptix® Colors
• Expansion of Dailies Total1® globally
 Focus on Japan Vision Care
Source Contact Lens and Lens Care estimates Contact Lens Institute/Euromcontact Factory Sales Sharing Program/GfK/Internal
Estimates; Market definition limited to Soft contact lens, and disinfectant solutions
92
Dailies Aqua Comfort Plus® portfolio expansion
Key Differentiators
Key Differentiators
 Add Toric and Multi-focal options
 Full brand family
 Regulatory approval received for Multi-Focal
and Toric
 US, EU, Japan, Canada, and Australia
launch planned for H1 2014
93
AirOptix® Colors to complete brand portfolio
Key Differentiators
Key Differentiators
 Provides breathable SiHy lens to consumers
interested in color options
 Combines plasma surface with realistic color
blend technology
 CE mark received October 2013
 FDA submission in October 2013
94
Continued expansion of Dailies Total1® in
Premium/Water Gradient SiHy segment...
Comfort continues to be the No. 1 need among contact lens wearers. Nearly 1 of 6
patients eventually discontinue use due to discomfort and dryness
LightStream® Lens
Technology
Water gradient
Silicone Hydrogel
Material Chemistry
95
DAILIES TOTAL1®
water gradient contact
lenses have the
highest surface
lubricity and
breathability of any
contact lens
delivering a new era
in comfort
...is expected to deliver continued
share gains...
Early Results in Daily Disposable SiHy Sphere Segment
1D TruEye
DT1
Italy DD1 SiHy Sphere
Revenue share percentage
+14
60
#1 Daily Disposable
premium lens
40
20
Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep
2012 2012 2012 2013 2013 2013 2013 2013 2013 2013 2013 2013
US DD SiHy Sphere
Revenue share percentage
100
50
+20
+20 share points
growth with early
limited launch
0
Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep
2012 2012 2012 2013 2013 2013 2013 2013 2013 2013 2013 2013
1DD
96
SiHy – Daily Disposable Silicon Hydrogel
... and Alcon is building capacity to grow globally
Production Capacity of Dailies Total1®
Millions of Units
1 200
+45%
 Currently, Dailies Total1® is
constrained by capacity
 To meet demand, Alcon is
investing to build capacity
0
2013
97
2014
2015
2016
2017
2018
Japan represents considerable opportunity
G7
US
Japan
EU Top 5
2,651,237
709,057
1,058,756
883,423
24%
37%
8%
35%
Latest 12 months - JUNE 2013
Daily Disposable CLEAR
USD '000
ALCON Share
Percentage
World’s largest
dailies market
Near-Term
Portfolio
Launches




Dailies Total1®
DACP® Professional
DACP® Multifocal and Toric
Air Optix® Colors
Source: GfK G7 Retail excluding Walmart June 2013
98
Execution
 Sales force expansion
 Messaging
 Channel pricing
Full Vision Care portfolio is key to category leadership
Market expansion
Surgical
LenSx®
ReSTOR® 2.5D
Intrepid®
Femtosecond
cataract laser
Multi-focal
Intraocular Lens
Minimally Invasive
Intraocular Lens
Luxor® LX3
Microscopes
Centurion®
Phacoemulsification
EX500® /FS200®
Refractive surgery
lasers
Ophthalmic
Pharmaceuticals
Simbrinza®
Glaucoma
Dailies Total1®
SiHy Lens
1sVMA=
2GA = Geographic Atrophy
99
Accommodative
Next generation
Intraocular Lens
Discussed
Today
ReSTOR® Toric
Intraocular Lens
LD Travoprost
Glaucoma
HD Olopatadine
Allergy
Jetrea®
sVMA1
Vision Care
ESBA 1008
Wet AMD3
PDE IV
Allergy
DACP4 Toric
HEMA lens
AirOptix® Color
SiHy Lens
DACP4 Multifocal
HEMA lens
Replenish® w/
ESBA1008
Wet AMD3
Complement
Inhibitor
GA2
DT15 Multifocal
SiHy Lens
DT15 Toric
SiHy Lens
DT15 Colors
SiHy Lens
Weekly WG6
SiHy Lens
Vision Care summary
Vision Care will focus on
 Innovation in building a differentiated portfolio
 Commercial execution in opportunity areas
100 | Investor Day | 22 November 2013 |
Agenda –
Summary – Projected revenue growth
Surgical
 New Phaco technology
 Toric IOL penetration - Verion™ surgical planning
 Intrepid® mono-focal IOL
Ophthalmic
Pharmaceuticals
 Jetrea® penetration and new treatment approach
 Retinal Rx entry
Vision Care
 Global Dailies Total1® portfolio launch
 Japan share development
 New SiHy weekly portfolio
Summary
 Ophthalmology continues to be an exciting space for growth driven
by:
•Favorable demographics
•Innovation
•Emerging Markets
 Alcon expected to grow faster than the industry in all franchises

Current Stage

Transcription

Similar documents

The author has no financial interest to disclose. How Many of your

LS-100/LS-200

Spec Sheet - N-Vision Optics PVS-7

Portatile e senza fili, per uno screening di qualità Portatile e senza

Givi V46 reflective decal installation instructions:

Kodak Total Blue™ Lens

Foster barriers with crossed beams produce a thick grid of crossed

elliptipar® with LED - The Lighting Quotient

Video Sunglasses, Sports HD 720p Wide Angle

Visit our Web-Site at www.starrett-precision.co.uk